Evidence map›Paper›PMID 42092908›Full record

ArticleBMC complementary medicine and therapies2026

Curcumin enhances the effects of TRAIL in TRAIL-resistant non-small cell lung cancer cell lines.

Nurul Izzah Mohd Pauzi, Noor Atiqah Fakharuzi, Nor Rizan Kamaluddin, Moon Nian Lim, Yuslina Mat Yusoff, Adiratna Mat Ripen, Kamal Shaik Fakiruddin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nurul Izzah Mohd Pauzi *Haematology Unit, Cancer Research Centre, Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health Malaysia, Shah Alam, 40170, Malaysia.
Noor Atiqah FakharuziHaematology Unit, Cancer Research Centre, Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health Malaysia, Shah Alam, 40170, Malaysia.
Nor Rizan KamaluddinHaematology Unit, Cancer Research Centre, Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health Malaysia, Shah Alam, 40170, Malaysia.
Moon Nian LimHaematology Unit, Cancer Research Centre, Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health Malaysia, Shah Alam, 40170, Malaysia.
Yuslina Mat YusoffHaematology Unit, Cancer Research Centre, Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health Malaysia, Shah Alam, 40170, Malaysia.
Adiratna Mat RipenHaematology Unit, Cancer Research Centre, Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health Malaysia, Shah Alam, 40170, Malaysia.
Kamal Shaik Fakiruddin *Haematology Unit, Cancer Research Centre, Institute for Medical Research (IMR), National Institutes of Health (NIH), Ministry of Health Malaysia, Shah Alam, 40170, Malaysia. kamal.shaik@moh.gov.my.ORCID http://orcid.org/0000-0003-3646-3317

Funding

Ministry of Health (MOH) of Malaysia NMRR ID-24-03258-GUF;24-091
6 · The paper itself

Abstract

backgroundTRAIL acts as a selective anticancer agent in non-small cell lung cancer (NSCLC). However, some NSCLC are resistance to TRAIL due to the presence of several anti-apoptotic mechanisms. With the help of natural compound such as curcumin, TRAIL-resistance can be overcome and the effect of TRAIL-induce apoptosis in NSCLC can be improved. In this study, we investigated the effect of curcumin in NSCLC as sensitiser to TRAIL as well as their molecular underlying mechanism.

methodProliferation assay was conducted to determine whether curcumin could enhance the cytotoxic effect of TRAIL in NSCLC cell lines. Flow cytometry was performed for the assessment of TRAIL receptors expression (DR4 and DR5) and apoptosis assay (Annexin-V / PI staining). Gene expression analysis using RT

resultsTreatment of NSCLC cell lines with TRAIL revealed that NSCLC cell lines can be classified as TRAIL-sensitive (H2170 and H1437) and TRAIL-resistant (A549 and H1299) based on their IC

conclusionHence, this study provides evidence on the potential of curcumin as a sensitiser to enhance the efficacy of TRAIL in NSCLC and in TRAIL-resistance NSCLC.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungCurcuminDrug Resistance, NeoplasmLung NeoplasmsTNF-Related Apoptosis-Inducing LigandApoptosisCell Line, TumorHumansReceptors, TNF-Related Apoptosis-Inducing LigandAntineoplastic AgentsCurcuminReceptors, TNF-Related Apoptosis-Inducing LigandTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humanApoptosisCurcuminLung cancerSensitisationTRAILTRAIL-resistant

Identifiers

PMID42092908
PMCPMC13551800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.